Information Provided By: 
Fly News Breaks for August 8, 2016
ELOS
Aug 8, 2016 | 07:10 EDT
Brean Capital noted Syneron Medical missed Q2 revenue estimates slightly, but beat on non-GAAP earnings. The firm believes the revenue miss was more internal management driven rather than a trend change. Brean Capital said given the stock's depressed valuation and the strong desire of management to turn around the company, they would be buyers of the shares. The firm reiterated its Buy rating and $13 price target on Syneron Medical shares.
News For ELOS From the Last 2 Days
There are no results for your query ELOS
